Corran Roberts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Corran Roberts has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ana Montes
Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust (GSTT), London SE1 9RT, UK
1 shared publication - Anna Schuh
University of Oxford, Oxford, United Kingdom
1 shared publication - Charlie Gourley
The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom
1 shared publication - Christopher Poole
University Hospital Coventry & Warwickshire NHS Trust, Coventry, UK
1 shared publication - Linda Collins
OCTO – Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, UK
1 shared publication - Lucy Boyle
OCTO – Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, UK
1 shared publication
Latest Publications
- Open Access
- 19 December 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 983
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been implicated in familial breast and ovarian cancer tumorigenesis. Tumour cells with these mutations demonstrate increased sensitivity to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors. 6MP was identified in a screen for novel drugs and found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AGO14699, even after these cells had acquired resistance to a PARP inhibitor or cisplatin. Exploiting the genetic basis of these tumours enables us to develop a more tailored approach to therapy for patients with BRCA mutated cancers.
- 19 December 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 983
Open AccessA phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been implicated in familial breast and ovarian cancer tumorigenesis. Tumour cells with these mutations demonstrate increased sensitivity to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors. 6MP was identified in a screen for novel drugs and found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AGO14699, even after these cells had acquired resistance to a PARP inhibitor or cisplatin. Exploiting the genetic basis of these tumours enables us to develop a more tailored approach to therapy for patients with BRCA mutated cancers.